Back to search
FDAFDA · Food and drugs·Recall number Z-1609-2024

t:connect mobile app used in conjunction with t:slim X2 insulin pump with Control-IQ technology

Published May 15, 2024 · Recall initiated: March 5, 2024

Summary

FDA records medical device Class I recall Z-1609-2024, published May 15, 2024 and initiated March 5, 2024. Recalling firm: Tandem Diabetes Care, Inc.; Status: Ongoing; Reported quantity: 85,863 applications; Lot: version 2.7 or later /UDI: 00850006613274. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

During normal use, the mobile app version 2.7 may crash and be automatically relaunched by the iOS operating system. This cycle intermittently repeats, which leads to excessive Bluetooth communication that may result in pump battery drain and may lead to the pump shutting down sooner than typically expected. Pump shutdown will cause insulin delivery to suspend, which could lead to an under-delivery of insulin and may result in hyperglycemia, including severe hyperglycemia.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Tandem Diabetes Care, Inc.
Distributor
US nationwide distribution including Puerto Rico.
Lot
version 2.7 or later /UDI: 00850006613274
Risk classification
Class I
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was t:connect mobile app used in conjunction with t:slim X2 insulin pump with Control-IQ technology recalled?

Yes. FDA published recall Z-1609-2024 on May 15, 2024. Reported hazard: During normal use, the mobile app version 2.7 may crash and be automatically relaunched by the iOS operating system. This cycle intermittently repeats, which leads to excessive Bluetooth communication that may result in pump battery drain and may lead to the pump shutting down sooner than typically expected. Pump shutdown will cause insulin delivery to suspend, which could lead to an under-delivery of insulin and may result in hyperglycemia, including severe hyperglycemia.

What should I do if I have this product?

Voluntary: Firm initiated · Letter